Jyong Biotech Ltd. Ordinary Shares
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $161.8M
- Price
- $2.18
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.93%
- Volume
- 17.4K
About
Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages
Quick stats
Shares outstanding74.2M
Computed float31.1M
Float / shares41.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001954488
Websitehttps://www.jyongbio.com/
AI Summary
AI-generated1/12
minorbullishoperations update
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
Jyong Biotech highlighted the growing market opportunity for Benign Prostatic Hyperplasia (BPH) treatments, projecting the global market will grow to $22.6 billion by 2035.
The company reaffirmed its strategic focus on pursuing global licensing partnerships for its lead drug candidate, Botreso, which is currently in Phase III trials.
Chairwoman Fu-Feng Kuo stated the company remains committed to addressing unmet medical needs in the aging population despite high discontinuation rates associated with current therapies.
Red flags
- Drug candidate Botreso remains investigational and is not approved for commercial use in any jurisdiction
- No definitive partnership agreements announced; release only references ongoing discussions